Article

Oncologist Lewis Silverman on Revlimid for Patients with Myelodysplastic Syndrome

Lewis Silverman, an oncologist with Mount Sinai Medical Center, discusses a clinical trial involving Revlimid (lenalidomide) for patients with a type of myelodysplastic syndrome.

Lewis Silverman, an oncologist with Mount Sinai Medical Center, discusses a clinical trial involving Revlimid (lenalidomide) for patients with a type of myelodysplastic syndrome.

Revlimid is currently approved for patients with a specific type of MDS that contains a chromosomal abnormality called deletion 5q.

The phase 3 trial,which was reported at the 2014 American Society of Hematology, includes patients with MDS who do not have the chromosomal abnormality but have low-risk disease.

The purpose of the study was to find out if Revlimid could reduce the number of red blood cell transfusions needed by anemic (transfusion-dependent) patients with low- or intermediate-risk MDS without a deletion 5q chromosome abnormality.

Silverman says the study confirms that about a quarter of patients who do not have the deletion 5q abnormality can become transfusion independent, and the duration of treatment response is about eight or nine months.

Newsletter

Stay up to date on cancer updates, research and education

Related Videos
Image of man with text.
Dr. Breelyn Wilky explains how vague symptoms and testing challenges delay GIST diagnoses
Mark Daniels, an 83-year-old veteran and former fighter pilot, was shocked by his lymphoma diagnosis because he maintained exceptional physical fitness.
Image of man with text.
Image of women, with text.
Image of Dr. with text.
Daniel Jernazian, who beat cancer twice, credits his sports mindset for survival and calls it winning his ‘life World Championship’.
Patients in rural or underserved areas may have worse outcomes, highlighting the need for early support to address care access barriers.
Image of man with text.
Dr. Emre Yekedüz discusses how ASCO 2025 highlights precision medicine, biomarkers and the gut microbiome as keys to advancing kidney cancer care.